Literature DB >> 7935861

The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor.

T Oláh1, K Régely, Y Mándi.   

Abstract

Allopurinol, a xanthine oxidase inhibitor, impaired the cytotoxic effect of human recombinant tumor necrosis factor (TNF) against WEHI cells. Actinomycin D abolished the inhibition of cytotoxicity by allopurinol. Allopurinol also exerted an inhibitory effect on the production of TNF by human mononuclear cells stimulated by either heat-killed Staphylococcus aureus or E. coli lipopolysaccharide. It is suggested that allopurinol inhibits TNF cytotoxicity by decreasing the level of oxygen free radicals generated (among other mechanisms) by the action of xanthine oxidase. Whatever the mechanism, the fact that allopurinol counteracts the toxicity of TNF can help towards an understanding of the complex nature of TNF toxicity.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7935861     DOI： 10.1007/bf00180017

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


  26 in total

Review 1.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

Review 2.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) messenger RNA (mRNA) expression in HL-60 leukemia cells by pentoxifylline and dexamethasone: dissociation of acivicin-induced TNF-alpha and IL-1 beta mRNA expression from acivicin-induced monocytoid differentiation.

Authors:  J B Weinberg; S N Mason; T S Wortham
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

4.  Mediator-induced activation of xanthine oxidase in endothelial cells.

Authors:  H P Friedl; G O Till; U S Ryan; P A Ward
Journal:  FASEB J       Date:  1989-11       Impact factor: 5.191

5.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

Authors:  T Espevik; J Nissen-Meyer
Journal:  J Immunol Methods       Date:  1986-12-04       Impact factor: 2.303

6.  Inhibition of urate production by allopurinol.

Authors:  T Spector
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

7.  Mediation of mouse natural cytotoxic activity by tumour necrosis factor.

Authors:  J R Ortaldo; L H Mason; B J Mathieson; S M Liang; D A Flick; R B Herberman
Journal:  Nature       Date:  1986 Jun 12-18       Impact factor: 49.962

8.  Tumor necrosis factor production by human granulocytes.

Authors:  Y Mándi; V Endrész; L Krenács; K Régely; M Degré; I Béládi
Journal:  Int Arch Allergy Appl Immunol       Date:  1991

9.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

10.  Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia.

Authors:  J Gelin; C Andersson; K Lundholm
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701
View more
  7 in total

Review 1.  Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.

Authors:  Kara Bradford; David Q Shih
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Allopurinol ameliorates thioacetamide-induced acute liver failure by regulating cellular redox-sensitive transcription factors in rats.

Authors:  Ulvi Demirel; Mehmet Yalniz; Cem Aygün; Cemal Orhan; Mehmet Tuzcu; Kazim Sahin; Ibrahim Hanifi Ozercan; Ibrahim Halil Bahçecioğlu
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

3.  Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.

Authors:  Miles P Sparrow
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-07

Review 4.  Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.

Authors:  T N Witte; A L Ginsberg
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

5.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

6.  Allopurinol reduces antigen-specific and polyclonal activation of human T cells.

Authors:  Damián Pérez-Mazliah; María C Albareda; María G Alvarez; Bruno Lococo; Graciela L Bertocchi; Marcos Petti; Rodolfo J Viotti; Susana A Laucella
Journal:  Front Immunol       Date:  2012-09-21       Impact factor: 7.561

Review 7.  Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring.

Authors:  Sheng Zhang Lim; Eng Wee Chua
Journal:  Front Pharmacol       Date:  2018-10-08       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.